Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aptensio XR Safety Study in Preschool Children with ADHD
NCT02677519Phase 4Unknown
- Sponsor
- Rhodes Pharmaceuticals
- Start
- Sep 2016
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of methylphenidate in attention deficit hyperactivity disorder (ADHD), sponsored by Rhodes Pharmaceuticals. Primary endpoints: Treatment-emergent adverse events at 12 months, Columbia Suicide Severity Rating Scale at 12 months and 2 more. Status: unknown.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02677519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02677519.